CSL Limited to commence clinical trial of A(H1N1) vaccine

NEW YORK A biopharmaceutical company in Australia has announced that it will soon begin a clinical trial of a vaccine against the A(H1N1) influenza, popularly known as swine flu.

CSL Limited announced Monday that the trial would take place in partnership with CMAX, a clinical research organization, and the Royal Adelaide Hospital in Adelaide, Australia. The trial will involve adults ages 18 to 64 who will receive two injections of the vaccine three weeks apart, meeting for four appointments over a six-month period.

“We understand flu vaccines very well from our long experiences with yearly seasonal strains, as well as research into novel flu vaccines,” CSL global director clinical development Russell Basser stated. “We appreciate that new influenza strains like the ‘swine flu’ can surprise us with properties that mean they might require higher dosing and two injections rather than one to provide the desired level of immune response in humans.”